Novavax Inc. (NVAX)
NASDAQ: NVAX
· Real-Time Price · USD
8.34
-0.30 (-3.47%)
At close: Sep 25, 2025, 3:59 PM
8.34
-0.01%
After-hours: Sep 25, 2025, 05:19 PM EDT
-3.47% (1D)
| Bid | 8.21 |
| Market Cap | 1.35B |
| Revenue (ttm) | 1.08B |
| Net Income (ttm) | 422.82M |
| EPS (ttm) | 2.22 |
| PE Ratio (ttm) | 3.76 |
| Forward PE | -96.33 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 8.47 |
| Volume | 4,361,172 |
| Avg. Volume (20D) | 6,281,373 |
| Open | 8.48 |
| Previous Close | 8.64 |
| Day's Range | 8.18 - 8.48 |
| 52-Week Range | 5.01 - 15.22 |
| Beta | 2.68 |
| Ex-Dividend Date | n/a |
About NVAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NVAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNovavax Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-4.08%
Shares of vaccine companies are trading lower foll...
Unlock content with
Pro Subscription
1 month ago
-12.7%
Novavax shares are trading lower after the company announced it has extended its $225 million convertible notes deal. Additionally, B of A Securities downgraded the stock yesterday from Neutral to Underperform and cut its price target from $9 to $7,
